Gurney M E, Liu R, Althaus J S, Hall E D, Becker D A
Pharmacia & Upjohn, Inc. Central Nervous System Diseases Research, Kalamazoo, Michigan, USA.
J Inherit Metab Dis. 1998 Aug;21(5):587-97. doi: 10.1023/a:1005475206997.
CuZn superoxide dismutase (CuZn SOD) is one of several antioxidant enzymes that defend the cell against damage by oxygen free radicals. Mutations of the SOD1 gene encoding CuZn SOD are found in patients with familial amyotrophic lateral sclerosis (FALS), a progressive and fatal paralytic disease that is caused by the death of motor neurons in cortex, brainstem and spinal cord. The disease can be reproduced in transgenic mice by expression of mutant human CuZn SOD. Recent studies both in vitro and in vivo suggest that the effect of mutation is to enhance the generation of oxygen radicals by the mutant enzyme. Thus, mutation converts a protective, antioxidant enzyme into a destructive, prooxidant form that catalyses free radical damage to which motor neurons are selectively vulnerable. Recent studies of neuroprotective agents in the FALS model show that inhibition of oxidative mechanisms (copper chelation therapy, dietary antioxidants, and coexpression of bcl-2) delays disease onset but does not extend disease duration. In contrast, inhibition of glutamatergic or apoptotic mechanisms (riluzole, gabapentin, and coexpression of glutamatergic or apoptotic mechanisms (riluzole, gabapentin, and coexpression of an inhibitor of caspase-1) has no effect on disease onset but extends survival by increasing the duration of symptomatic disease. Thus, neuroprotective agents differentially target the processes underlying disease initiation and propagation.
铜锌超氧化物歧化酶(CuZn SOD)是几种抗氧化酶之一,可保护细胞免受氧自由基的损伤。在家族性肌萎缩侧索硬化症(FALS)患者中发现了编码CuZn SOD的SOD1基因突变,FALS是一种进行性致命性麻痹疾病,由皮质、脑干和脊髓中的运动神经元死亡引起。通过表达突变型人CuZn SOD可在转基因小鼠中重现该疾病。最近的体外和体内研究表明,突变的作用是增强突变酶产生氧自由基的能力。因此,突变将一种保护性抗氧化酶转化为一种具有破坏性的促氧化形式,这种形式催化自由基损伤,而运动神经元对这种损伤具有选择性易感性。最近在FALS模型中对神经保护剂的研究表明,抑制氧化机制(铜螯合疗法、膳食抗氧化剂和bcl-2共表达)可延迟疾病发作,但不会延长疾病持续时间。相比之下,抑制谷氨酸能或凋亡机制(利鲁唑、加巴喷丁和caspase-1抑制剂共表达)对疾病发作没有影响,但通过增加症状性疾病的持续时间来延长生存期。因此,神经保护剂以疾病起始和传播的不同潜在过程为靶点。